Regeneron and its close partner Sanofi have posted another set of promising results for dupilumab--which targets the interleukin-4 and interleukin-13 inflammatory proteins--from a Phase IIb study that backs up those high expectations.
Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers.
Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.
Three years after Takeda decided to double down on motesanib for non-small cell lung cancer, in-licensing full rights to the drug from Amgen following their big Phase III failure in 2011, the company has once again come up empty-handed in a major late-stage test of the therapy.
It took a while for VBL Therapeutics to actually complete its IPO last year. And this morning it may be wishing it hadn't succeeded as its stock price crashed following the failure of its midstage studies of a new drug for psoriasis and ulcerative colitis.
Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.
SINGAPORE-- MerLion Pharmaceuticals announced Wednesday that the U.S. FDA has approved an otic suspension of finafloxacin to treat acute otitis externa, commonly known as "swimmer's ear."
SINGAPORE-- Cellular Biomedicine Group has bought chimeric antigen receptor T cell therapies from the Chinese PLA General Hospital in a deal valued at RMB12 million ($1.9 million) to be paid in three installments.
SINGAPORE-- Several Japan drugmakers are making strides toward being major pioneers in the new pharmaceuticals field of nucleic acid-based treartments. A few already have clinical trials in the works for such things as Duchenne muscular dystrophy.
Regulus Therapeutics upped the dosage of its microRNA hepatitis C therapy RG-101 in a small study and gathered evidence of a bigger impact on patients' viral loads. But investigators also added new evidence that the treatment was far less durable than the new therapies hitting the marketplace, sending a shiver through the market this morning.